ViS Research

ViS Research is an American-based, multinational company that optimizes clinical trial planning through a structured, online feasibility platform. The platform provides tools and analytics to pharmaceutical and biotechnology companies and contract research organizations that transform how locations, research centers and investigators are evaluated for inclusion in clinical trials.

All the multi-dimensional inputs are integrated and made easily accessible through novel visualization methods. At the same time, ViS enables research centers to create an online profile, which answers over 85 percent of questions raised in feasibility assessments. Networking tools facilitate communication and engagement between trial planners and centers. The ViS platform is transforming the feasibility process using the same web technologies that have transformed the consumer web.

ViS Research, Inc.
Incorporated
Industry Clinical Research Analytics technology
Information Technology
Analytics
Founded New York, USA (2010)
Founder Fabio Thiers, MD, PhD
Romero Tavares
Headquarters 32 W 86th St, New York, NY, United States
Number of locations
 United States
Brazil
Germany
India
Area served
 Worldwide
Key people
 Fabio Thiers (CEO)
Richard Kivel (COO)
Gustavo Kesselring (Executive Director LATAM)
Dan Martines (CIO)
Chuck Swanson (Head of Sales)
Marc Wilenzick (Head of Stakeholder Engagement)
James Rosenstein (Head of Global Communications)
Johanna Schenk (Executive Director Europe)
Jatin Shah (Executive Director Asia)
Products Location Analytics
Center Analytics
Analytics Services
Number of employees
 50+ (April 1, 2013)
Slogan The power of online feasibility
Website www.visresearch.com

Overview

ViS' online feasibility platform streamlines the process of finding and assessing researchers and research centers for clinical trials, using public and private data together with advanced analytics. The platform uses an intuitive, highly navigable, graphical interface to facilitate finding active research centers in a given therapeutic area, at the country, state, city, or postal code level. The ViS platform also allows research centers to provide technical information about their expertise and internal capabilities in conducting trials within specific disease areas, and networking features enable trial planners and research centers to connect immediately. One of the main benefits of the platform is that it obviates the need for repetitive and cumbersome feasibility questionnaires. Headquartered in New York City, ViS has offices in Brazil, Germany and India.

ViS provides up-to-date, advanced analytics on clinical research infrastructure and personnel, individual research centers, investigator profiles, curated patient demographics, and public and private research center networks. Examples include information about ongoing trials, number of trials per center, available patients, and patient engagement levels (number of patients enrolled in clinical research per 100,000 patients in a city or location). Individual trial centers can display information about their expertise and capabilities, including detailed information about their research staff, aggregate patient demographics, infrastructure, capabilities and research, as part of their ViS profile. ViS Profile (example)


Novel location analytics showing the number of trials at site-level and growth rate for all diseases in the top 50 countries.

ViS' analytics cover over 400,000 disease-specific research sites. A key feature is the novel combination of location analytics compiled by ViS (i.e. aggregate patient demographics and trial engagement metrics) with site-specific data provided by the Research Centers.

ViS integrates information from three primary data sources, through collaborative analytics: internal research, research sites and investigators, and 3rd party data. The company uses parsing algorithms, natural language processing, and pattern recognition to curate and harmonize data from public and private sources. All information is then continuously harmonized and integrated using proprietary semantic technologies to generate disease-specific analytics. The data is then geo-referenced and integrated with crowd-sourced inputs from individual research centers.[1] In January 2014, InVentiv Health Clinical, a leading drug developer, reported that it had analyzed data from 100 feasibility studies to determine the value of using ViS analytics for trial feasibility. According to Inventiv, its assessment of ViS's platform showed a reduction in "mean feasibility time by 54%. Inventiv's Senior Vice-President and General Manager of its Clinical Trial Recruitment Services noted that its leveraging of the efficiencies were expected to continue, noting that "[i]n the next phase of development on the ViS platform we'll accelerate [our feasibility] processes even more." [2]

Users of ViS' collaborative analytics include pharmaceutical, biotechnology, medical device and diagnostic companies, academic and government institutions, contract research organizations (CROs) and other organizations around the world engaged in clinical trials.

ViS was featured at TedMed in April 2013 as part of the Hive.[3][4]

On May 7th, 2013, ViS announced a partnership with the Biotechnology Industry Organization (BIO) to map the pediatric populations of multiple countries to facilitate pediatric research. The release noted that such research was often frustrated by the complexity of finding patients for such research, even though about 60% of the disease burden for high priority conditions is borne by children.[[5] ViS has also announced strategic collaborations with the accreditation agency, AAHRPP (the Association for the Accreditation of Human Research Protection Programs), and with one of the largest networks of clinical trial research sites, BRANY (Biomedical Research Alliance of New York).[6] In August, 2013, the Alliance for Clinical Research Excellence and Safety (ACRES) announced a collaboration with ViS in the launch of a global clinical research network technology platform.[6]

ViS Research was founded by Dr. Fabio Thiers, who used to be the Director of MIT's Strategic Global Trials research program.[7]

Technology

ViS is the only feasibility platform that enables location selection, site/investigator selection and engagement in one sitting. In so doing it greatly facilitates clinical trial planning. It also provides the first and only fully integrated map of global clinical research activity and infrastructure. This is done through the use of proprietary algorithms that collect and harmonize disaggregated clinical research information, about ongoing research and local demographics, globally. In this way, ViS maps country, state, city and local disease-specific patient populations, ongoing research activity, research infrastructure and investigators, all within a specific disease and region.

ViS' analytics include the following:

  1. Location Analytics: provides an interactive way to view location-specific information about patients, research activity, infrastructure, and research personnel for each disease covered
  2. Location Profile: provides detailed analytics and scoring metrics, main research centers, and top research locations about each location
  3. Advanced Center Analytics: enables instantaneous access to over 400,000 disease-specific sites all over the world
  4. Investigator Analytics: enables trial planners to extensively evaluate and compare both general and disease-specific investigator information.
  5. Network analytics: makes it possible to quickly determine the aggregate capabilities of research center networks and access their shared infrastructure
  6. Partner Profile: provides analytics about site networks, SMOs, accreditation organizations, and many others
  7. Feasibility management: enables the organization and management of research center evaluation and communication at scale

Innovation timeline

2003-2010

2010-2012

2013–present

Key Facts

  • 178 Countries
  • 400,000+ Disease-specific centers
  • 360,000 Investigators
  • 1,376 epidemiological databases
  • 148,366 Trials
  • 1,165,729 trial at site level
  • 59,000 Institutional Profiles
  • >85% of feasibility questions
  • 67 diseases with feasibility instrument
  • 69 diseases with patient mapping
  • >80% of clinical trial collaborations
  • 7,900 FDA Inspections

References

  1. ↑ http://visresearch.com/servlet/Controller?cmd=trialplanners
  2. ↑ http://www.prnewswire.com/news-releases/inventiv-health-leverages-advanced-digital-technology-to-slash-the-time-required-to-conduct-feasibility-studies-241640041.html
  3. ↑ http://www.tedmed.com/files/Downloads/TEDMED2013Program.pdf
  4. ↑ http://www.tedmed.com/files/DelegatePDF/TEDMED%202013%20Delegates.pdf
  5. ↑ http://online.wsj.com/article/PR-CO-20130507-911627.html?mod=googlenews_wsj
  6. 1 2 http://www.visresearch.org/servlet/Controller?cmd=news
  7. 1 2 http://www.nature.com/nrd/journal/v7/n1/suppinfo/nrd2441.html

External links

See also

This article is issued from Wikipedia - version of the Tuesday, February 09, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.